<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03906799</url>
  </required_header>
  <id_info>
    <org_study_id>OMT28-C0201</org_study_id>
    <nct_id>NCT03906799</nct_id>
  </id_info>
  <brief_title>Study on OMT-28 in Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation (AF)</brief_title>
  <acronym>PROMISE-AF</acronym>
  <official_title>A Placebo-controlled, Double-blind, Randomized, Dose-finding Phase II Study on OMT-28 in MaIntenance of Sinus Rhythm After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation (PROMISE-AF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Omeicos Therapeutics GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Omeicos Therapeutics GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, dose-finding, placebo-controlled, parallel group,
      multicenter, phase II study to evaluate the efficacy, safety, and popPK of three different
      doses of OMT-28 given once daily versus placebo in patients with persistent AF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, dose-finding, placebo-controlled, parallel group,
      multicenter, phase II study to evaluate the efficacy, safety, and popPK of three different
      doses of OMT-28 given once daily versus placebo in patients with persistent AF. At
      randomization, the duration of the current episode of persistent AF must be shown to be
      greater than 7 days and not greater than 3 months, as confirmed by two ECGs (one ECG must be
      a 12-lead ECG) and further patient enquiry (including doctor visits, hospital admissions,
      symptom onset, etc.).

      A sample size re-evaluation will be performed to avoid an underpowered study because of
      imprecise estimates for the study population or overoptimistic parameter estimates.
      Therefore, an interim analysis will re-evaluate sample size assumptions after approximately
      15 patients per study arm (~50 % of planned sample) have completed the treatment phase (Visit
      8) of the study. Predefined rules will govern the decision for adjustment of sample size.

      Patients will be monitored for cardiac events throughout the study using an Implantable
      Cardiac Monitor (ICM). Safety will be monitored throughout the study. Blood samples will be
      collected in pre-specified windows for popPK analysis and at pre-specified timepoints for
      PK/PD analysis. Patients will be provided with a diary to record timing of drug
      administration and clinical symptoms while not on site. Diaries will be reviewed and checked
      for compliance at each non-resident visit to the clinical site.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2019</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of AF Burden After OMT-28 Administration</measure>
    <time_frame>Up to 4.5 months</time_frame>
    <description>To assess the AF burden, based on data collected via the implantable cardiac monitor BioMonitor 2-AF, of three different doses of OMT-28 administered once daily versus placebo in the maintenance of normal sinus rhythm after electrical direct current cardioversion (DCC) in patients with persistent AF</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Up to 4.5 months</time_frame>
    <description>To assess the incidence of treatment-emergent Adverse Events of three different doses of OMT-28 administered once daily versus placebo after electrical DCC in patients with persistent AF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Pharmacokinetic (PK) Parameters of OMT-28 - AUC</measure>
    <time_frame>Up to 3.5 months</time_frame>
    <description>To assess the pharmacokinetic (PK) parameter AUC of OMT-28 administered once daily in patients with persistent AF, by means of population PK (popPK) analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Pharmacokinetic (PK) Parameters of OMT-28 - Cmax</measure>
    <time_frame>Up to 3.5 months</time_frame>
    <description>To assess the pharmacokinetic (PK) parameter Cmax of OMT-28 administered once daily in patients with persistent AF, by means of population PK (popPK) analysis.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Concentration of NT-proBNP</measure>
    <time_frame>Up to 3.5 months</time_frame>
    <description>To assess the concentration of the exploratory, pharmacodynamic (PD) parameter NT-proBNP after once-daily administration of OMT-28 or placebo in patients with persistent AF.</description>
  </other_outcome>
  <other_outcome>
    <measure>Concentration of GDF-15</measure>
    <time_frame>Up to 3.5 months</time_frame>
    <description>To assess the concentration of the exploratory, pharmacodynamic (PD) parameter GDF-15 after once-daily administration of OMT-28 or placebo in patients with persistent AF.</description>
  </other_outcome>
  <other_outcome>
    <measure>Concentration of MMP-9</measure>
    <time_frame>Up to 3.5 months</time_frame>
    <description>To assess the concentration of the exploratory, pharmacodynamic (PD) parameter MMP-9 after once-daily administration of OMT-28 or placebo in patients with persistent AF.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Low OMT-28</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Verum, low OMT-28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Middle OMT-28</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Verum, middle OMT-28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High OMT-28</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Verum, high OMT-28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OMT-28</intervention_name>
    <description>1 capsule given daily orally from Visit 3 (Day 1) to Visit 8 (Day 99 ± 3 days).</description>
    <arm_group_label>High OMT-28</arm_group_label>
    <arm_group_label>Low OMT-28</arm_group_label>
    <arm_group_label>Middle OMT-28</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 capsule given daily orally from Visit 3 (Day 1) to Visit 8 (Day 99 ± 3 days).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females between 18 and 85 years of age.

          -  Patients with persistent AF for &gt; 7 days but ≤ 3 months suitable for electrical DCC.

          -  Male patients must be surgically sterile for at least 90 days or will be required to
             use a male condom with spermicide, and will refrain from donating sperm from the time
             of the first dose until 90 days after the last dose of study medication.

          -  Females of childbearing potential (postmenarchal, not surgically sterile,
             premenopausal) will agree to follow contraception requirements from the time of
             signing the Informed Consent Form (ICF) until 90 days after the last administration of
             study drug.

          -  Willing and able to give written informed consent before any study-related procedure.

          -  Willing and able to attend all the visits scheduled in the study.

        Main Exclusion Criteria:

          -  Patients with known concurrent temporary secondary causes of AF

          -  Patients that have undergone surgical or catheter ablation for AF or atrial flutter.

          -  Patients with an existing cardiac treatment device, pacemaker, implantable
             cardioverter defibrillator, or cardiac resynchronization therapy.

          -  Patients with a history of ECG abnormalities that, in the opinion of the investigator
             (or designee), render the patient unsuitable for the study.

          -  Patients with congestive heart failure (NYHA class III and IV).

          -  Patients with left atrium size ≥ 55 mm.

          -  Patients with left ventricular ejection fraction ≤ 40 %.

          -  Known presence of a thrombus in the left atrial appendage, left atrium, left
             ventricle, aorta, or intracardial mass.

          -  Patients with moderate or severe mitral stenosis, mitral valve rheumatic disease,
             unresected atrial myxoma, or a mechanical heart valve and/or other conditions, such as
             pulmonary embolism, considered to be formal indication for conventional
             anticoagulation.

          -  Patients with any acute coronary event, stroke, or percutaneous coronary intervention
             within 6 months prior to randomization or who are receiving dual antiplatelet therapy.

          -  Uncontrolled/therapy-resistant bradycardia and/or uncontrolled/therapy-resistant
             hypertension within a 3-month period prior to randomization.

          -  Patients having more than two DCCs in the last 6 months. Any unsuccessful
             pharmacological and/or electrical cardioversion (within prior 3 months).

          -  Patients with signs of bleeding or conditions associated with a high risk of bleeding.

          -  Patients taking antiarrhythmic agents within 3 days of planned randomization will be
             excluded.

          -  Patients concurrently participating in another study or unable to communicate.

          -  Patients with active cancer, chronic kidney disease or intercurrent illness.

          -  Pregnant or breastfeeding women.

          -  Patients taking concomitant medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Gebauer, Dr.med.</last_name>
    <role>Study Director</role>
    <affiliation>Managing Director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Gebauer, Dr.med.</last_name>
    <phone>+49 30 94894810</phone>
    <email>a.gebauer@omeicos.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luciana Summo, Dr.rer.nat.</last_name>
    <phone>+49 30 94894810</phone>
    <email>l.summo@omeicos.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site 401</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 404</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6004</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 402</name>
      <address>
        <city>Varna</city>
        <zip>9000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 301</name>
      <address>
        <city>Kolín</city>
        <zip>28002</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 303</name>
      <address>
        <city>Plzen</city>
        <zip>30460</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 302</name>
      <address>
        <city>Slaný</city>
        <zip>27401</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 205</name>
      <address>
        <city>Budapest</city>
        <zip>1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 201</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 203</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 206</name>
      <address>
        <city>Hódmezővásárhely</city>
        <zip>6800</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 202</name>
      <address>
        <city>Pécs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 204</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 102</name>
      <address>
        <city>Cherkasy</city>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 110</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 104</name>
      <address>
        <city>Kharkiv</city>
        <zip>61018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 107</name>
      <address>
        <city>Kharkiv</city>
        <zip>61176</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 108</name>
      <address>
        <city>Khmelnytskyi</city>
        <zip>29000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 113</name>
      <address>
        <city>Kiev</city>
        <zip>02660</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 106</name>
      <address>
        <city>Kiev</city>
        <zip>03038</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 101</name>
      <address>
        <city>Kiev</city>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 109</name>
      <address>
        <city>Kiev</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 112</name>
      <address>
        <city>Kiev</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 105</name>
      <address>
        <city>Odesa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 103</name>
      <address>
        <city>Uzhgorod</city>
        <zip>88000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 111</name>
      <address>
        <city>Zhytomyr</city>
        <zip>10002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Ukraine</country>
  </location_countries>
  <link>
    <url>http://www.omeicos.com/</url>
    <description>OMEICOS Therapeutics GmbH</description>
  </link>
  <reference>
    <citation>Schunck WH, Konkel A, Fischer R, Weylandt KH. Therapeutic potential of omega-3 fatty acid-derived epoxyeicosanoids in cardiovascular and inflammatory diseases. Pharmacol Ther. 2018 Mar;183:177-204. doi: 10.1016/j.pharmthera.2017.10.016. Epub 2017 Nov 7. Review.</citation>
    <PMID>29080699</PMID>
  </reference>
  <reference>
    <citation>Fischer R, Konkel A, Mehling H, Blossey K, Gapelyuk A, Wessel N, von Schacky C, Dechend R, Muller DN, Rothe M, Luft FC, Weylandt K, Schunck WH. Dietary omega-3 fatty acids modulate the eicosanoid profile in man primarily via the CYP-epoxygenase pathway. J Lipid Res. 2014 Jun;55(6):1150-64. doi: 10.1194/jlr.M047357. Epub 2014 Mar 16.</citation>
    <PMID>24634501</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 20, 2019</study_first_submitted>
  <study_first_submitted_qc>April 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2019</study_first_posted>
  <last_update_submitted>April 5, 2019</last_update_submitted>
  <last_update_submitted_qc>April 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Electrical Cardioversion</keyword>
  <keyword>Dose-finding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

